The KLHDC9 Knockout HEK293T Polyclonal Cells product comprises a population of human embryonic kidney HEK293T cells engineered via CRISPR/Cas9 technology to disrupt the KLHDC9 gene. This polyclonal knockout cell pool provides a potent loss-of-function model for studying the role of KLHDC9 in the ubiquitin-proteasome system. The CRISPR-mediated gene disruption abrogates KLHDC9 protein expression, enabling functional investigations without the confounding effects of clonal selection. As a mixed population, these cells maintain the genetic heterogeneity inherent to polyclonal editing, making them suitable for experiments requiring robust and representative knockout models.
HEK293T cells are a highly transfectable derivative of the HEK293 line, originally isolated from human embryonic kidney tissue. They stably express the SV40 large T antigen, which permits episomal replication of plasmids carrying the SV40 origin of replication, thereby enhancing recombinant protein production and lentiviral packaging efficiency. Their epithelial-like morphology and rapid growth in adherent culture make them a versatile platform for biochemical and cell-based assays. The HEK293T background is particularly advantageous for studying ubiquitin ligase complexes, as it supports high-level expression of co-transfected pathway components and enables sensitive detection of post-translational modifications.
KLHDC9 (Kelch domain-containing protein 9) is a predicted substrate recognition adaptor of Cullin-RING E3 ubiquitin ligase (CRL) complexes. It directly interacts with the core scaffold components CUL3 and RBX1, forming a functional E3 ligase module that facilitates the transfer of ubiquitin from E2 conjugating enzymes to target substrates. This ubiquitination typically signals proteins for proteasomal degradation. The precise upstream signals regulating KLHDC9 remain undefined, though cellular stress pathways may modulate its activity. Its downstream effectors are equally enigmatic, as the endogenous substrates recruited by KLHDC9 for ubiquitination have yet to be identified. Decoding this substrate landscape is critical to understanding how KLHDC9 governs protein homeostasis.
In the HEK293T cellular context, disruption of KLHDC9 offers a clean genetic background to interrogate its contribution to substrate degradation networks. The cell line??s ease of manipulation allows for complementation studies using wild-type or mutant KLHDC9 constructs, enabling dissection of structure-function relationships. Given the proposed link between aberrant protein degradation and cancer, this knockout model serves as a valuable tool for probing tumor-suppressive or oncogenic consequences of impaired KLHDC9 function. Moreover, the HEK293T system supports biochemical reconstitution assays, such as co-immunoprecipitation, to validate interactions with CUL3 and RBX1 or to screen for novel binding partners.
Typical applications include proteomic identification of KLHDC9 substrates using differential ubiquitin enrichment or SILAC-based mass spectrometry, cycloheximide chase experiments to measure substrate protein stability, and in vitro ubiquitination assays to recapitulate the CUL3?CKLHDC9 ligase activity. These cells are also suitable for functional genomics screens aimed at uncovering synthetic lethal vulnerabilities or pathway dependencies linked to KLHDC9 loss. Researchers can employ western blotting with ubiquitin-specific antibodies to monitor global ubiquitylation changes upon knockout. This validated polyclonal knockout model equips investigators with a reliable resource to advance the mechanistic understanding of Cullin-RING E3 ligases. For further technical information, please contact Ascent Research.
